Provectus Q3 10-Q: $180,733 Cash, Going Concern Doubt Persists
PVCT is trading near its 52-week low of $0.038 (8.4% above the low) on elevated volume (9.7× avg).
Summary
Provectus reported $180,733 of cash and a $6.7 million working capital deficit at September 30, 2026, with management repeating that substantial doubt exists about its ability to continue as a going concern. The nine-month net loss narrowed to $3.56 million, funded entirely by convertible note sales.
Key Events · Earnings and Guidance · PVCT
-
Going Concern Doubt Reiterated
Management states the company's cash position and recurring losses raise substantial doubt about its ability to continue as a going concern for one year from issuance of the financial statements.
-
Cash Falls to $180,733
Cash dropped from $251,291 at December 31, 2025 to $180,733 at September 30, 2026, while the working capital deficit widened to $6,730,268 from $6,329,504.
-
Nine-Month Loss Narrows to $3.56M
Net loss for the nine months ended September 30, 2026 was $3,563,375 versus $4,337,312 a year earlier, driven by research and development expense falling to $704,784 from $1,628,848.
-
$1.7M Raised Via Convertible Notes
The company received $1,695,000 of 2025 Notes proceeds in the nine months, including $240,000 from an officer and director; $2,796,514 of principal and interest on those notes auto-converts to preferred stock at maturity.
Analysis · PVCT · Life Sciences
Provectus closed September 30, 2026 with just $180,733 of cash against a $6,730,268 working capital deficit, and management states these conditions raise substantial doubt about the company's ability to continue as a going concern within one year. The loss narrowed — nine-month net loss of $3,563,375 versus $4,337,312 a year earlier — but that came mostly from cutting research spending, not from revenue, since the company still generates nothing from product sales. The only cash coming in is convertible debt: $1,695,000 of 2025 Notes raised in the nine months, with $2,796,514 of principal and interest on those notes set to auto-convert to preferred stock at maturity. Existing holders face continued dilution as that debt converts into Series D-1 Preferred Stock at $2.862 per share.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PVCT was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $17.3M. The 52-week trading range was $0.04 to $0.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.